

510(k) Summary
Advia Retic Plus Hematology Control

Date of Summary: February 16, 2001
Company Name: R&D Systems, Inc.
614 McKinley Place N.E.
Minneapolis, MN 55413
Contact name: Kenneth T. Edds, Ph.D.
612-379-2956, FAX 612-379-6580
Classification name: multiparameter hematology control
Classification code: 81JPK Hematology Control mixtures for
Quality Control
Product name: Advia Retic Plus Hematology Control
CFR section: 864.8625
Device Class: Class II

Device to which substantial equivalence is claimed:
Advia Testpoint Reticulocyte Hematology Control, manufactured by Streck Laboratories.
510(k) number: K993825.

The product is an *in vitro* diagnostic reagent composed of human erythrocytes and avian erythrocytes in a plasma-like fluid with preservatives. Advia Retic Plus is composed of stable materials that provide a means of monitoring the performance of the Advia hematology systems. Advia Retic Plus is currently validated only for the Advia 120 analyzer. Advia Retic Plus is available in three levels and allows the control of multiple reticulocyte parameters. Advia Retic Plus is used and tested in the same manner as patient samples.

Intended use: Advia Retic Plus is a tri-level, assayed hematology control designed to monitor values obtained from automated reticulocyte counting methods. Refer to the assay table for specific instrument models.

Advia Retic Plus Hematology Control has an intended use that is identical to the predicate device. The technologies of the two devices are similar.

Nonclinical testing of 2 validation lots centered on the performance attributes of stability and precision. Advia Retic Plus Hematology Control passed the acceptance criteria of remaining within the assay range over the life of the product. Advia Retic Plus Control also demonstrated precision as indicated by the small standard deviations and %CVs obtained during testing and was comparable to the predicate device. Expiration dating has been established at 60 days in the customers hands (closed vial) and 14 days, or 14 entries, open vial when stored at 2-8°C and handled according to instructions for use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

APR - 3 2001

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Kenneth T. Edds, Ph.D.
Director, RA/QA
R & D Systems Inc.
614 McKinley Place N.E.
Minneapolis, MN 55413

Re: 510(k) Number: K010461
Trade/Device Name: ADVIA Retic Plus Hematology Control
Regulation Number: 864.8225
Regulatory Class: II
Product Code: JPK
Dated: February 16, 2001
Received: February, 16, 2001

Dear Dr. Edds:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number: K010461

Device Name: ADVIA Retic Plus Hematology Control

Indications for Use:

ADVIA Retic Plus™ is a tri-level, assayed hematology control designed to monitor values obtained from automated reticulocyte counting methods. Refer to assay table for specific instrument models.

Joseph Z. Radtke
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K010461

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)